All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
John L. Bradley, Jr.
Manager
Raleigh, North Carolina
2/12/2019
The securities listed in the information table are held by NovaQuest Pharma Opportunities Fund III, L.P. ("Fund III"), NovaQuest Pharma Opportunities Fund III (Aggregator), L.P. ("Fund III Aggregator"), NovaQuest Pharma Opportunities Fund IV, L.P. ("Fund IV"), and NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. ("Fund IV Parallel" and collectively with Fund III, Fund III Aggregator, and Fund IV, the "NovaQuest Funds"), as applicable. The filing of this report or any related report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, or for any other purpose, that NovaQuest Capital Management, L.L.C. ("NovaQuest Capital") or any other person exercises investment discretion with respect to the securities listed herein or is a member of, or is otherwise affiliated with, such a group with respect to such securities. Reference is made, where relevant, to reports filed under Sections 13(d), 13(g) and 16(a) of the Exchange Act for additional information with respect to such beneficial ownership and/or pecuniary interest of securities held by the NovaQuest Funds. The filing of this report or any related report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Exchange Act and the rules thereunder, or for any other purpose, that NovaQuest Capital or any other person is the beneficial owner of any securities held by the NovaQuest Funds.
Other Included Managers (3):
Num
Name
Location
File Number
2
NovaQuest Pharma Opportunities Fund III, L.P.
028-16648
3
NQ HCIF General Partner, L.P.
028-16646
4
NQ HCIF GP, Ltd.
028-16645
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.